Pelareorep
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Breast Cancer
Conditions
Advanced or Metastatic Breast Cancer
Trial Timeline
Oct 11, 2021 → May 30, 2023
NCT ID
NCT05519059About Pelareorep
Pelareorep is a phase 1 stage product being developed by Adlai Nortye for Advanced or Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05519059. Target conditions include Advanced or Metastatic Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Breast Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05519059 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced or Metastatic Breast Cancer